Anderson Compounding Pharmacy (Anderson Compounding Pharmacy, Inc.), Bristol, TN

Is Anderson Compounding Pharmacy (Anderson Compounding Pharmacy, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Anderson Compounding Pharmacy (Anderson Compounding Pharmacy, Inc.) hold a Tennessee pharmacy license?

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. The Colorado State Board of Pharmacy also lists nonresident license OSP 6243 for Anderson Compounding Pharmacy, Bristol, TN, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018768 for ANDERSON COMPOUNDING PHARMACY INC, BRISTOL, TN, status NOT RENEWED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002554 for ANDERSON COMPOUNDING PHARMACY, BRISTOL, TN, status INACTIVE (DOES NOT WISH TO RENEW), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001304 for Anderson Compounding Pharmacy, Bristol, TN, status Expired, as of Nov 10, 2026.

Has Anderson Compounding Pharmacy (Anderson Compounding Pharmacy, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jan 13, 2020), 1 warning letter close-out (Feb 17, 2022), 1 state handoff letter (Feb 17, 2022) and 1 FMD-145 letter (Feb 17, 2022) for Anderson Compounding Pharmacy (Anderson Compounding Pharmacy, Inc.). State board actions: no Tennessee Board of Pharmacy action under this exact name and city was found in the Board of Pharmacy sections of the Tennessee Department of Health’s monthly Disciplinary Action Reports (actions dated January 2004 to April 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Anderson Compounding Pharmacy, Inc.; Anderson Compounding Pharmacy
Location
Bristol, TN
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
1
Latest action on that page
Feb 17, 2022
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 4 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Anderson Compounding Pharmacy, Inc. (dba Anderson Compounding Pharmacy), a 503A facility, with 5 dated actions.

Document
Feb 17, 2022State handoff letterState Handoff Letter Issued 02/17/2022Not linked by FDA
Feb 17, 2022FMD-145 letterFMD-145 Letter Issued 02/17/2022Not linked by FDA
Feb 17, 2022Warning letter close-outWarning Letter Closeout Issued 02/17/2022Not linked by FDA
Jan 13, 2020Warning letterWarning Letter (01/13/2020)fda.gov
Apr 5, 2019Form 483483 Issued 04/05/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Anderson Compounding Pharmacy, Inc., Bristol, TN (FEI number 3014877770), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 9, 2021No Action Indicated (NAI)Drug Quality Assurance (Drugs)30148777701153267
Apr 5, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30148777701085801

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 26, 2019 to Apr 5, 2019: 4 observations

Firm on the cover
Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy, Attn: Cleve Anderson, 310 Bluff City Hwy, Bristol, TN 37620-4 602
FEI number
3014877770
Establishment type on the cover
Producer of Sterile and Non-Sterile Human and Veterinarian Drugs
FDA district office on the cover
404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The ISO 5 classified aseptic processing areas had difficult to clean and visibly dirty equipment or surface.

Specifically, on 03/26/2019, we observed the following in your firm's ISO 5 classified areas, where aseptic human and veterinarian drug production take place, including, but are not limited to:

A. Inside your fnm's Laminar Air Flow Hoods (LAFH) (ISO 5 classified):

1. Visible discoloration that appears to be rust was observed inside your firm's LAFH (ISO 5 classified), SIN: <Redacted B4>

2. Visible discoloration that appears to be residue buildup was observed on your firm's LAFH (ISO 5 classified), SIN: <Redacted B4> where the workbench meets the HEPA screen;

3. Paint was observed, and confirmed by your firm's technician 1hat performs aseptic processing on the inside of the LAFHs (ISO 5 classified) (SIN: <Redacted B4> & S/N <Redacted B4> appearing to cover areas where discoloration resembling what appeared to be rust was observed, and

4. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Non-microbial contamination was observed in your production area.

Specifically, in your fnm's Buffer Room (ISO 5 classified), including, but are not limited to:

A. Visible discoloration that appears to be rust was observed around the nuts and bolts, located on the top of your fnm 's entiy door separating the AnteRoom (ISO 7 classified) from your fnm's Buffer Room (ISO 5 classified);

B. Visible discoloration that appears to be rust was observed around the nut, located on the outside of your firm's LAFHs (ISO 5 classified), SIN: <Redacted B4>

E. What appeared to be packaging tape was observed on your ceiling. The packagmg tape was adhered to a fallen light fixture and an adjacent ceiling tile; and

C. Visible discolorati

on <Redacted B4> was observed on your firm's HEPA filters, located on the ceiling above your firm's

D. Visible discoloration that appears to be residue buildup was observed on your firm's fixtures, located above your firm's LAFHs (ISO 5 classified) (SIN: <Redacted B4> & SIN: <Redacted B4>

F. Caulking was observed on the ceiling of your firm's Buffer Room (ISO 5 classified). The caulking is not smooth and not easily cleanable. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Unsealed, loose ceiling tiles were observed in your cleamoom.

Specifically, gaps were observed on the ceiling of your firm's Buffer Room (ISO 5 classified). For example, but are not limited to:

A. Gaps were observed in your firm's light fixture:

1. Ranging from approximately 0"-1/2" wide and 48" long was observed, located directly above your firm's Biological Safety Cabinet (BSC) (ISO 5 classified), where your firm aseptically produces hazardous sterile drug products.

2. Ranging from approximately 2-3" wide was observed, located directly above your firm's LAFH (ISO 5 classified), SIN: <Redacted B4>

B. Gaps were observed in your firm's ceifing tiles:

1. A gap <1/4" wide was observed on the ceiling above your firm's <Redacted B4>

Observation 4

You produced hazardous drugs without providing adequate containment to prevent cross-contamination.

Specifically, your firm did not provide documentation supporting smoke studies were performed under dynamic conditions during the routine certification of your ISO 5 classified areas.

State board of pharmacy records

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions in the data are dated January 2004 to April 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 6243OSPAnderson Compounding PharmacyBristol, TNExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018768LICENSED PHARMACYANDERSON COMPOUNDING PHARMACY INCBRISTOL, TNNOT RENEWED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002554NONRESIDENT PHARMACYANDERSON COMPOUNDING PHARMACYBRISTOL, TNINACTIVE (DOES NOT WISH TO RENEW)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001304Non Resident PharmacyAnderson Compounding PharmacyBristol, TNExpired

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.